The natriuretic peptide (NPs) family includes atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). ANP is primarily secreted by atrial myocytes, BNP is mainly secreted by ventricular myocytes, and CNP is predominantly secreted by vascular endothelial cells. The primary physiological functions of natriuretic peptides include promoting natriuresis and diuresis, inhibiting the renin-angiotensin-aldosterone system, and dilating blood vessels.
Previous studies have shown that NPs exert their effects by binding to natriuretic peptide receptor 1 (NPR1), which is the receptor for ANP and BNP. This binding activates downstream guanylyl cyclase, promoting the synthesis and increasing the levels of cyclic guanosine monophosphate (cGMP). As a second messenger in downstream signaling cascades, cGMP mediates effects such as natriuresis, diuresis, and vasodilation, thereby contributing to blood pressure reduction.
Genomeditech provides a variety of research tools related to the NPR1 target, including overexpression cell lines, functional cell lines, proteins, and antibodies. These resources comprehensively support the in vitro activity validation of related drugs, providing strong support for researchers in evaluating and optimizing drug development, and facilitating their application and translation in disease treatment.
